Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 10:28:07 23/05/2024 pm IST			5-day change	1st Jan Change
0.2 ^USD	-9.09%		-9.09%	-70.01%

16/04	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
16/04	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Advaxis, Inc. Appoints Shelonitda S. Rose as Vice President, Clinical Development

July 08, 2015 at 06:35 pm IST

Advaxis, Inc. announced that it has appointed Shelonitda S. Rose, M.D., as Vice President, Clinical Development. Dr. Rose brings to Advaxis more than 15 years of experience in medical oncology and hematology clinical research. In her role as Vice President, Clinical Development, Dr. Rose will report to Advaxis's Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical development programs for the Company's Lm Technology™ platform.

Most recently, Dr. Rose served as Director, Oncology Clinical Research for Merck & Co., Inc.

Latest news about Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04	DJ
North American Morning Briefing : Focus Turns to -2-	04/04	DJ
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	04/04	CI
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	04/04	CI
North American Morning Briefing : Stocks Set for -2-	28/03	DJ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	25/03	CI
North American Morning Briefing : Fed's Preferred -2-	29/02	DJ
North American Morning Briefing : Nvidia Ignites -2-	22/02	DJ
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	20/02	CI
Sector Update: Health Care Stocks Gain Late Afternoon	07/02	MT
Top Midday Gainers	07/02	MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	07/02	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	06/02	CI
North American Morning Briefing : Stock Futures -2-	27/11	DJ
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/11	CI
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	20/11	DJ
Ayala Pharmaceuticals, Inc. announced that it has received $4 million in funding from Israel Biotech Fund, Arkin Bio Venture Partners Ltd., BioTelemetry, Inc.	17/11	CI
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	23/23/23	CI
Ayala Pharmaceuticals, Inc. Announces Executive Changes	21/23/21	CI
BioSight Ltd. acquired Ayala Pharmaceuticals, Inc. in a reverse merger transaction.	18/23/18	CI
North American Morning Briefing : Stock Futures Point Lower Ahead of Big Bank Earnings	13/23/13	DJ
North American Morning Briefing : Investors Await -2-	06/23/06	DJ
North American Morning Briefing : Mood Improves as -2-	29/23/29	DJ

Chart Ayala Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.22

Average target price

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AYALA PHARMACEUTICALS, INC.	-70.01%	93.79L
MODERNA, INC.	+65.12%	6.26TCr
IQVIA HOLDINGS INC.	-1.29%	4.12TCr
LONZA GROUP AG	+44.76%	4.03TCr
CELLTRION, INC.	-8.93%	2.79TCr
ICON PUBLIC LIMITED COMPANY	+13.37%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	1.91TCr
BIO-TECHNE CORPORATION	+4.98%	1.31TCr
UNITED THERAPEUTICS CORPORATION	+25.70%	1.23TCr
MEDPACE HOLDINGS, INC.	+28.41%	1.21TCr

Other Biotechnology & Medical Research